loading page

Rare tumors in pediatric patients: first report in Argentina
  • +6
  • Alejandra Casanovas,
  • Marianela Viso,
  • Guido Felizzia,
  • Adriana Rose,
  • Celeste Mattone,
  • Natalia Gazek,
  • Bettina Cervini,
  • Carlos Giuseppucci,
  • Walter Cacciavillano
Alejandra Casanovas
Hospital General de Niños Pedro de Elizalde
Author Profile
Marianela Viso
Paediatric Hospital Dr Juan Garrahan
Author Profile
Guido Felizzia
Hospital de Pediatría Prof Dr Juan P Garrahan
Author Profile
Adriana Rose
Paediatric Hospital Dr Juan Garrahan
Author Profile
Celeste Mattone
Hospital de Pediatría Prof Dr Juan P Garrahan
Author Profile
Natalia Gazek
Hospital de Pediatría Prof Dr Juan P Garrahan
Author Profile
Bettina Cervini
Hospital de Pediatría Prof Dr Juan P Garrahan
Author Profile
Carlos Giuseppucci
Hospital de Pediatría Prof Dr Juan P Garrahan
Author Profile
Walter Cacciavillano
Hospital de Pediatría Prof Dr Juan P Garrahan
Author Profile

Abstract

Background Cooperative clinical trials has increased the knowledge on pediatric tumors, however, this is not the case for rare tumors (RT). Objective To describe the incidence, clinical characteristics and outcome of RT in the pediatric age diagnosed at Garrahan Hospital. Material and methods Retrospective descriptive study of patients (pts) between 0 and 18 years admitted between January 2 007 and December 2 017, with diagnosis of RT. Results Of 1 657 pts with diagnosis of solid tumors, 164pts (9.9%) corresponded to RT, 71.95% (118pts) were under 14 years old and 81.7% (130pts) were male. In order offrequency RT were: thyroid carcinoma (ca) 60pts, adrenal ca 14pts, lung tumors 14pts, melanoma 13pts, salivary glands ca 11pts, gastrointestinal tumors 8pts, non-gonadal germinal tumors 7pts, pancreatic tumors 7pts, renal ca 6pts, nasopharyngeal ca 5pts, pheochromocytoma/paraganglioma 5pts, timo 1pte. The treatment received depended on the type of tumor and stage. With a median follow-up of 34.9 months (range: 1- 128.5 months), 133pts (78.7%) are alive and only 10pts (6%) were lost to follow-up. Conclusion Knowing these initial data will allow us to propose new registration strategies and to develop multidisciplinary proposals for diagnosis, treatment and follow-up.